Squarepoint
INDP icon

Squarepoint’s Indaptus Therapeutics INDP Stock Holding History

Squarepoint’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-171
Closed -$67K – 3149
2021
Q2 		$67K Buy
+171
New +$75.3K ﹤0.01% 3074
2020
Q4 		– Sell
-36
Closed -$20K – 3079
2020
Q3 		$20K Sell
36
-18
-33% -$13.2K ﹤0.01% 2419
2020
Q2 		$35K Buy
+54
New +$33.4K ﹤0.01% 2131
2019
Q3 		– Sell
-59
Closed -$577K – 2492
2019
Q2 		$577K Buy
59
+50
+556% +$631K 0.01% 1582
2019
Q1 		$141K Buy
+9
New +$158K ﹤0.01% 2000

Other funds holding INDP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Squarepoint's INDP Position: Q3 2021 in Review

Squarepoint sold out of Indaptus Therapeutics (INDP) in Q3 2021, closing a stake of 171 shares — an estimated $67K sold.

Squarepoint first reported a position in INDP in Q1 2019 and held it in 5 quarters. The position peaked at $577K in Q2 2019. 14 funds tracked by Wall St. Rank hold INDP as of Q3 2021.

  • Squarepoint reported no remaining Indaptus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Squarepoint sold 171 Indaptus Therapeutics shares in Q3 2021, an estimated $67K.
  • Squarepoint first reported a position in Indaptus Therapeutics in Q1 2019 and held it in 5 quarters.
  • Squarepoint's Indaptus Therapeutics position peaked at $577K in Q2 2019.
  • 14 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.